Sector News

Alexion to create 200 jobs in Dublin expansion

May 12, 2015
Life sciences
Biopharma group Alexion has announced plans for a major expansion of its Irish business.
 
Alexion, which is still building the first page of its planned Dublin base, said it will invest a further € 450 million to extend the facility over the next four years.
 
The expansion will see the US-based specialist in rare and ultra rare diseases construct its first biological manufacturing facility outside the US.
 
The company makes Soliris, one of the world’s most expensive drugs, which is used to treat two rare blood conditions.
 
The drug, which costs in the region of € 430,000 per patient per year, received approval for use in Ireland earlier this year after a protracted negotiation.
 
Alexion expects to create 200 jobs with the investment, nearly doubling the numbers employed in Ireland by the company since its arrival here in 2013.
 
Alexion’s Irish executive VP for global operations Julie O’Neill said the project “further underscores our commitment to Ireland and is enabled by our ability to recruit highly competent and professional personnel”.
 
Tanaiste Joan Burton welcomed the announcement and said the company brought the “miracle of hope to parents of children who have life limiting and life threatening conditions”.
 
Also speaking at the announcement, Minister for Enterprise Richard Bruton characterised Alexion as a “wonderful company” whose founders “have fantastic passion”.
 
By Dominic Coyle
 
Source: Irish Times

comments closed

Related News

December 3, 2023

FDA names chief scientist Bumpus as Woodcock’s successor

Life sciences

The Food and Drug Administration’s top scientist Namandjé Bumpus will assume the role of principal deputy commissioner when longtime agency leader Janet Woodcock retires from that role in early 2024, according to an announcement Thursday.

December 3, 2023

AbbVie to buy cancer drug maker ImmunoGen for $10.1 Billion

Life sciences

US biopharma AbbVie has agreed to acquire ImmunoGen in a deal which values the company at about $10.1 billion and gives AbbVie access to flagship cancer therapy Elahere (mirvetuximab soravtansine-gynx), a first-in-class antibody-drug conjugate (ADC) approved for platinum-resistant ovarian cancer (PROC), as well as a pipeline of promising next-generation ADCs.

December 3, 2023

EuroAPI appoints new Executive Committee members

Life sciences

EUROAPI today announced the appointment of David Seignolle as Chief Operating Officer, succeeding Eric Berger, and Marion Santin as Chief Legal, Compliance, and IP Officer, both joining the company’s Executive Committee. In his new role, David Seignolle will lead the transformation of the Industrial Operations organization.

How can we help you?

We're easy to reach